Syntekabio
Founded Year
2009Stage
IPO | IPOTotal Raised
$33.2MDate of IPO
12/17/2019Market Cap
160.83BAbout Syntekabio
Syntekabio is a genomic big data and AI-driven drug discovery & development company. The company uses its computational biology technologies for drug candidate discovery. It also specializes in co-developing drug response biomarkers of existing drug candidates, which allows improvement of the likelihood of successful clinical trials, biomarker-driven indication expansion, and enhanced understanding of the drug's mechanism of action.
Syntekabio Headquarter Location
Migun Techno World, Building 2-B, Room 512 187, Techno 2-ro, Yuseong-gu
Daejeon, 34025,
South Korea
+82 070-7663-0958
Research containing Syntekabio
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Syntekabio in 2 CB Insights research briefs, most recently on Sep 12, 2019.
Expert Collections containing Syntekabio
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Syntekabio is included in 4 Expert Collections, including Artificial Intelligence.
Artificial Intelligence
8,694 items
This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.
Omics
1,265 items
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Digital Health
12,795 items
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Biopharma Tech
838 items
Syntekabio Patents
Syntekabio has filed 6 patents.
The 3 most popular patent topics include:
- Genetics
- Learning methods
- Machine learning
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
3/18/2021 | 1/4/2022 | Betacoronaviruses, Animal virology, Viral respiratory tract infections, Animal viral diseases, Zoonoses | Grant |
Application Date | 3/18/2021 |
|---|---|
Grant Date | 1/4/2022 |
Title | |
Related Topics | Betacoronaviruses, Animal virology, Viral respiratory tract infections, Animal viral diseases, Zoonoses |
Status | Grant |
Latest Syntekabio News
Nov 19, 2021
JW Pharmaceutical, Syntekabio to co-develop new drugs using AI 바로가기 기자명 Lee Han-soo 닫기 JW Pharmaceutical said that it would cooperate with Syntekabio in developing innovative new drugs based on artificial intelligence. JW Pharmaceutical CEO Lee Sung-yeol (left) and Syntekabio CEO Jung Jong-sun hold the cooperation agreement at Syntekabio's Guro Supercom Center in Guro-gu, southwestern Seoul, on Thursday. Under the accord, the two companies will expand the scope of existing joint research to discover first-in-class candidate materials that target specific disease-causing proteins. They will also accelerate the discovery of innovative drug candidates using the AI drug development platform and drug 3D simulation technology secured by Syntekabio. In 2018, the two companies signed a research cooperation agreement to identify biomarkers of new drug candidates under development by using Syntekabio's drug reactivity prediction technology. They will also cooperate to expand indications for new drug pipelines and repurpose existing drugs. "We are very happy to strengthen the friendly cooperative relationship with JW Pharmaceutical and to expand the scope of cooperation by using our DeepMatcher solution to enter into joint research for new drug development targeting specific target proteins," Syntekabio CEO Jung Jong-sun said. "Through close cooperation between the two companies, we will make active efforts to achieve innovative results in the field of AI-based drug development in the future." JW Pharmaceutical CEO Lee Sung-yeol also said, "The development of basic science has allowed us to identify new protein pathways and correlations between diseases, and competition for new drug development targeting them is fierce." Based on Syntekabio's big data and AI-based technology, the company will speed up the development of new medicines tailored to patients, Lee added.
Syntekabio Web Traffic
Syntekabio Rank
You May Also Like
Proteorex Therapeutics aims to discover therapeutics for diseases using a small-molecule drug discovery platform that integrates a synthesis design strategy, computational modeling, and patient-derived cell-based screening.
PharmCADD develops Pharmulator, a computer-aided drug discovery and development platform that utilizes computational science methodologies, advanced machine learning technologies, and molecular dynamics.
Cloud Pharmaceuticals, formerly TeraDiscoveries, is a leader in the computational design of new drugs and subsequent rapid, information-driven drug development. The company accelerates the drug discovery and design process in a way that delivers tangible results and true value for partners.
BioSolveIT visualizes drug discovery. Its software enables every chemist to advance their research. Perceptive visualization helps the users to understand computational results at a glance.
Modulus Discovery is a preclinical-stage technology-driven drug discovery company dedicated to accelerating the discovery of new medicines for patients and their families through the synthesis of computational intelligence, biological inspiration, and global integration. The company is focused on the rapid design and generation of small molecule clinical candidates for a range of high-value disease targets through the use of its computational drug discovery expertise and biology insights.
PharmEnable is a drug discovery company that uses a combination of medicinal chemistry and AI computational approaches to design small molecule drugs.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.